EyePoint (EYPT) Other Operating Expenses (2011 - 2026)
EyePoint (EYPT) posted Other Operating Expenses of -$82.4 million for Q1 2026, down 119.96% sequentially from $413.1 million in Q4 2025, and down 775.62% YoY from $12.2 million in Q1 2025.
Analysis
EyePoint (EYPT) Other Operating Expenses (2011 - 2026) Analysis & Trends
EyePoint has reported Other Operating Expenses for 13 years, with the latest figure at -$82.4 million in Q1 2026.
- Quarterly Other Operating Expenses fell 775.62% year-over-year to -$82.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $272.6 million (up 254.87% YoY) and the FY2025 annual result came in at $223.1 million, up 5705.49% from the prior year.
- Other Operating Expenses eased to -$82.4 million in Q1 2026 per EYPT's latest filing, from $413.1 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at $413.1 million in Q4 2025 and troughed at -$88.6 million in Q4 2024.
- A 5-year average of $8.1 million and a median of $765000.0 in 2024 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2024 and 2025: Other Operating Expenses sank 2421.89% in 2024, then soared 566.19% in 2025.
- Over 5 years, Other Operating Expenses stood at $39.9 million in 2022, then plunged by 222.32% to -$48.8 million in 2023, then sank by 81.74% to -$88.6 million in 2024, then jumped by 566.19% to $413.1 million in 2025, then slumped by 119.96% to -$82.4 million in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered -$82.4 million, $413.1 million, and -$58.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31,000.00 |
| Mar 31, 2026 | 531,000.00 |
| Dec 31, 2025 | 369,000.00 |
| Sep 30, 2025 | 747,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 840,000.00 |
| Dec 31, 2024 | 867,000.00 |
| Sep 30, 2024 | 760,000.00 |
| Jun 30, 2024 | 1.45 Mn |
| Mar 31, 2024 | 765,000.00 |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | 1.68 Mn |
| Jun 30, 2023 | 7.08 Mn |
| Mar 31, 2023 | 6.38 Mn |
| Dec 31, 2022 | 30.23 Mn |
| Sep 30, 2022 | 8.04 Mn |
| Jun 30, 2022 | 9.23 Mn |
| Mar 31, 2022 | 9.09 Mn |
| Dec 31, 2021 | 18.78 Mn |
| Sep 30, 2021 | 9.81 Mn |